
Oncology NEWS International
- Oncology NEWS International Vol 5 No 7
- Volume 5
- Issue 7
Corrections to an Article By Peter Kennedy, MD
Oncology News International would like to correct two errors that appeared in Dr. Peter Kennedy's article on space sharing (May 1996, page 12), as part of the Oncology & Managed Care series edited by Dr. Cary Presant.
Oncology News International would like to correct two errors thatappeared in Dr. Peter Kennedy's article on space sharing (May1996, page 12), as part of the Oncology & Managed Care seriesedited by Dr. Cary Presant.
Dr. Kennedy is president and founder of Metropolitan OncologyMedical Group, Inc., Los Angeles. Dr. Armand Bouzaglou, a radiotherapistwho shares space with Dr. Kennedy's group, does not have an exclusivecontract with Dr. Kennedy to provide radiation therapy servicesfor his patients. The editors apologize for these errors.
Articles in this issue
almost 30 years ago
Princess Diana Helps Raise Over $1 Million for Cancer Researchalmost 30 years ago
Study Gives Terminal Patients Option: $18,000 or More Treatmentalmost 30 years ago
Proven: Colorectal Screening Cuts Deaths 50%almost 30 years ago
Virtual Colonoscopy Technique Feasible in Detecting Polypsalmost 30 years ago
Trimetrexate Appears Beneficial in Colorectal Canceralmost 30 years ago
FDA Liaison Program Answers Patients' Questions About Trialsalmost 30 years ago
New Company Joins With RPR To Develop Intrabody Technologyalmost 30 years ago
More Insurers Covering ABMT, Despite Lack of Efficacy Dataalmost 30 years ago
CDC Says Teen Smoking Still RisingNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Related Content



135 Elacestrant in Combination With Everolimus or Abemaciclib in Patients With ER+/HER2– Locally Advanced or Metastatic Breast Cancer (mBC): Phase 2 Results From ELEVATE, an Open-Label, Umbrella Study

TIP136 ELEGANT: Elacestrant Versus Standard Endocrine Therapy (ET) in Women and Men With Node-Positive, Estrogen Receptor–Positive (ER+), HER2-Negative (HER2–), Early Breast Cancer (eBC) With High Risk of Recurrence in a Global, Multicenter, Randomized, Open-Label Phase 3 Study















































